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Aim of the work: To describe the clinical features of patients with Sjögren’s syndrome (SS) in a single-
center cohort and to investigate factors that may influence duration till disease diagnosis.
Patients and methods: This cross-sectional study is based on the local registry of SS patients at the
Rheumatology Department of Dnipropetrovsk Mechnikov Regional Hospital, Ukraine. Data from the first
admission of 24 patients; 1 male and 23 females with a median age of 54 years (45–61 years) was ana-
lyzed.
Results: In patients with primary SS (n = 19) the disease appeared at the age of 44 years (37–49 years)
and the most common symptom to emerge first was ocular/oral dryness (OOD); in patients with sec-
ondary SS (n = 5) the disease mostly manifested with Raynaud’s phenomenon/rash/myalgia at the age
of 28.6 years (27–37 years). Patients with primary SS more commonly had elevated antinuclear antibody
(ANA) titer, anemia, higher IgG and lower glomerular filtration rate; patients with secondary SS more fre-
quently exhibited skin changes, myocarditis, heart failure and higher IgA. Median duration till diagnosis
was 8.5 years (2.8–17 years). Onset of SS with fever or Raynaud’s phenomenon/rash/myalgia shortened
the duration till diagnosis. Presence of C-reactive protein >6 mg/dl or ANA > 1:320 may indicate primary
SS in patients with symptoms of OOD. On the contrary, combination of OOD at the disease onset and pos-
itive rheumatoid factor significantly increased the duration till SS diagnosis.
Conclusions: The median duration till diagnosis of SS is prolonged. Patients with symptoms of OOD at dis-
ease onset had significantly prolonged duration till diagnosis.
 2019 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Sjögren’s syndrome (SS) is a chronic autoimmune disease, a
hallmark of which is affection of lachrymal and salivary glands
along with extraglandular manifestations and presence of autoan-
tibodies [1]. SS can further be distinguished as primary (pSS), in
which the disease is limited to dry eye and/or mouth symptoms,
and secondary (sSS), in which above mentioned symptoms accom-
pany another systemic disease [1]. Epidemiology and clinical man-
ifestations of SS vary significantly among ethnic groups and
geographical areas that may contribute to difficulties in diagnosis
establishment [2–4]. Whereas in several countries of European
region SS is considered as an orphan disease [5], it is supposed tobe the second prevalent rheumatic disease [6]. Although >90% of
patients present with sicca syndrome [7], these complaints are
rather non-specific and are difficult to classify [8]. Patients from
Northern Europe experience ocular dryness two times less fre-
quently than in other geographical regions [4]. This leads to an
average 3.9-year delay in diagnosis and treatment initiation, as
well as under diagnosis of SS in more than in half affected patients
[8]. Hematological and immunological markers are widely used in
diagnosis of SS and prediction of its complications [9–12]. Role of
autoantibodies in SS, even in the absence of systemic manifesta-
tions is highly appreciated, moreover, according to revised 2016
ACR/EULAR diagnostic criteria presence of autoantibodies has the
same impact on the SS diagnosis establishment as salivary gland
biopsy [12]. In the study of the Dutch prospective diagnostic cohort
anti-SSA (Ro) antibody titer was even more specific for SS diagno-
sis, than labial or parotid salivary gland focus score [13]. Strong
association of primary SS with hypergammaglobulinemia G sup-
ports the idea of autoimmune origin of SS [6,14]. Hypergamma-
globulinemia and hypercomplementemia were predictive ofal clin-
2 O. Kuryata et al. / The Egyptian Rheumatologist xxx (xxxx) xxxprogression to SS in individuals with incomplete diagnostic
criteria [15].
To our knowledge, this is the first study concerning clinical
characteristics of the patients with SS in Ukrainian region. This
study is the earliest to define how laboratory findings available
in primary care may influence the time of SS diagnosis from the
moment of the first symptom development. The aim of the present
work is to describe the clinical features of patients with SS in a
single-center cohort and to investigate factors that may influence
duration of SS diagnosis.
2. Patients and methods
This cross-sectional study is based on the local registry of
patients with SS at Dnipropetrovsk Mechnikov Regional Hospital,
Dnipro, Ukraine. The register was established in 2018 and contains
data on 24 SS patients (1 male and 23 females) with a median age
of 54 years (45;61) who received medical care at the Rheumatol-
ogy Department from 2007 to 2019. Data from patients’ medical
records on the first admission was analyzed. Diagnosis of SS was
provided according to the 2002 American-European Consensus
Group criteria [10]. All the patients gave their informed written
consent on data collecting and processing. The study was approved
by the Ethics Committee of Dnipropetrovsk Mechnikov Regional
Hospital (protocol number 703/17-1 from 6 June 2017).
2.1. Symptoms of SS onset
The first manifestation of SS and time of its emergence was col-
lected from patients’ medical records. Fever was considered as rise
of body temperature >37Celsius. Arthritis was defined as swellingTable 1
Comparison of clinical characteristics of the patients in the study with primary and secon
Parameter n(%) or median (IQR) Sjögren’s syndrome patients (n =
All (n = 24)
General characteristics
Females 23 (95.8)
Age (years) 54 (45.5–61)
BMI 24.2 (19.8–26.5)
SBP (mmHg) 120 (110–150)
DBP (mmHg) 80 (70–82)
Age at first symptom (years) 41.5 (33.5–48.2)
Time till diagnosis (years) 8.5 (2.8–17)
First symptom
Fever 3 (12.5)
Arthritis 5 (20.8)
Ocular/oral dryness 9 (37.5)
Signs of systemic diseases 8 (33.3)
Diagnostic criteria
Objective xerostomia 23 (95.8)
Stomatitis 7 (29.2)
Decreased salivary glands 2 (13.3)
Enlarged salivary glands 10 (66.7)
Dry keratoconjunctivitis 21 (87.5)
Need for artificial eye drops 18 (75.0)
Rheumatoid factor (>14 IU/l) 13 (54.2)
ANA positive 5 (31.3)
Laboratory findings
GFR (ml/min) 88 (74–101)
Proteinuria 6 (26.1)
Anemia 10 (41.7)
ESR (>25 mm/h) 12 (50)
CRP (>5 mg/l) 8 (33.3)
Cryoglobulinemia 9 (45.0)
IgG (g/l) 14 (9–19)
IgA (g/l) 3.1 (2.3–3.8)
IgM (g/l) 2.1 (1.2–3.2)
pSS: primary SS; sSS: secondary SS; BMI: body mass index; SBP: systolic blood pressu
filtration rate; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; Ig: immun
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were assessed according to the 2002 criteria [10]. SS onset with
symptoms of other systemic disorders was established in patients
reporting Raynaud’s phenomenon, rash (any location) or myalgias
as the first manifestation. All the patients with symptoms of ocular
or oral dryness were prescribed cholinolytic drugs, artificial saliva
and eye drops. 19 patients (79.1%) were prescribed low-dosage
steroids (15 mg/day); 7 (29.1%) were treated with hydroxychloro-
quine and 4 patients (16.6%) were prescribed other immunosup-
pressive drugs (leflunomide, cyclophosphamide).
2.2. Clinical manifestations
Diagnosis of dry keratoconjunctivitis was provided by an
ophthalmologist. For objective confirmation of xerostomia and
evaluation of salivary glands enlargement patients were referred
to oral and maxillofacial surgery department. Raynaud’s
phenomenon was diagnosed if patient experienced episodes of
paleness/cyanosis/hyperemia of fingers after exposure to cold or
emotional stress and after nail fold video capillaroscopy. Arterial
hypertension was diagnosed if systolic blood pressure was
140 mmHg or diastolic 90 mmHg on hospital admission or
when using antihypertensives. Diagnosis of myocarditis was taken
from patients’ medical records. None of the patients had acute
myocarditis. The mean pulmonary artery pressure (PAPm) and
presence of pericardial effusion were assessed during transthoracic
echocardiography. Left ventricle hypertrophy was diagnosed using
Sokolow-Lyon criteria [16]. Pulmonary fibrosis was diagnosed
using chest X-ray or computerized tomography. Gastritis was
diagnosed after esophago-gastroduodenoscopy. Diagnosis of pan-
creatitis was based on patients’ complaints, changes in stool testdary Sjögren’s syndrome.
24)
pSS (n = 19) sSS (n = 5) p
18 (94.7) 5 (1 0 0) 1
56 (47.5–61) 50 (36–52) 0.3
23.6 (20.9–25.9) 24.9 (19.4–32.7) 0.61
120 (117–155) 110 (110–120) 0.09
80 (70–90) 75 (75–78) 0.44
44 (37–49.5) 28.6 (27–37) 0.11
8 (3–14) 13 (2–18) 0.77
2 (10.5) 1 (20) 0.52
4 (21.1) 1 (20) 1
9 (47.7) 0 (0) –
6 (31) 2 (40) 1
18 (94.7) 5 (1 0 0) 1
5 (26.3) 2 (40) 0.6
2 (15.4) 0 (0) –
8 (61.5) 2 (1 0 0) 0.52
17 (89.5) 4 (80) 0.52
14 (73.7) 4 (80) 1
11 (57.9) 2 (50) 0.62
5 (41.7) 0 (0) –
78 (70–97) 101 (94–102) 0.13
6 (31.6) 0 (0) –
10 (52.6) 0 (0) –
6 (31.6) 2 (50) 1
6 (31.6) 2 (50) 1
7 (41.2) 2 (66.7) 0.56
14.6 (9.9–20.1) 6.9 (3.7–10.2) 0.056
2.9 (2.2–3.6) 3.8 (3.6–4.2) 0.16
2.1 (1.2–3.4) 2.2 (1.5–2.8) 1
re; DBP: diastolic blood pressure, ANA: antinuclear antibodies; GFR: Glomerular
oglobulin. IQR: interquartile range.
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Glomerular filtration rate (GFR) was calculated using Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [17].
Several laboratory findings were regarded as positive if they
exceeded the following thresholds: C-reactive protein (CRP)
> 6 mg/dl, rheumatoid factor (RF) > 14 IU/l, erythrocyte sedimenta-
tion rate (ESR) > 25 mm/h or antinuclear antibodies (ANA)
titer > 1:320.
Statistical analysis: Due to a small sample size (n < 30) non-
parametric statistic tools were used. Continuous data was
described as median (interquartile range) and compared with U
Mann-Whitney test. Categorical data was described as n (valid %)
with account for missing data and compared using Fisher’s exact
test. Time of SS diagnosis depending on the first symptomwas ana-
lyzed using Kaplan-Meier method. Significance of divergence of
survival curves was assessed with log-rank test. Data processing
was performed using The R Project for Statistical Computing
(GNU project, https://www.r-project.org/). The role of positive
CRP, RF, ESR or ANA in augmenting the diagnostic value of symp-
toms of ocular/oral dryness (OOD) at the disease onset has been
assessed aiming at a faster diagnosis of SS. In combination with
the OOD, the effect of each factor alone or together with others
was assessed. Influence of all combinations on duration of SS diag-
nosis was assessed using Cox proportional-hazards regression
models for all patients and separately for patients with pSS. A p-
values <0.05 was considered significant.
3. Results
The majority of patients were middle-aged females with normal
BMI and the disease onset in fourth decade of life (Table 1). SS wasTable 2
Extraglandular manifestations in patients with primary and secondary Sjögren’s syndrom
Parameter n(%) or median (IQR) Sjögren’s syndrome patients (n
All (n = 24)
Raynaud’s phenomenon 9 (37.5)
Polyarthritis 19 (79.2)
Skin rash 5 (20.8)
Hyperpygmentation 4 (16.7)
Skin atrophy 3 (12.5)
Thyroid gland anomaly 12 (75)
Heart failure 12 (63.2)
Hypertension 7 (29.2)
Myocarditis 10 (41.7)
LVH 5 (33.3)
Arrhythmia 6 (30)
Hydropericarditis 3 (21.4)
PAPm (mmHg) 24 (22–26)
Dyspnea 14 (58.3)
Pulmonary fibrosis 2 (11.8)
Gastritis 14 (58.3)
Pancreatitis 15 (62.5)
pSS: primary SS; sSS: secondary SS; LVH: left ventricle hypertrophy; PAPm: mean pulmo
Table 3
Time till diagnosis of Sjögren’s syndrome depending on the first symptom.
Symptom median (IQR) All SS patients (n = 24)
Present Absent
Fever 3 (2–5.5) 10 (3–17)
Arthritis 17 (11–20) 8 (2.5–12)
Salivary glands 11 (10–19) 5 (2.5–11)
Symptoms of AID 4.5 (2.7–10.2) 10.5 (2.7–17.5)
SS: Sjögren’s syndrome; pSS: primary SS; AID: autoimmune disease. Bold values are sig
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(SSc) in 3, to mixed connective tissue disease in 1 and to rheuma-
toid arthritis in 1). The most frequent findings were xerostomia
and dry keratoconjunctivitis. None of the patients with sSS had
OOD symptoms at the disease onset. The next most prevalent were
systemic manifestations, elevated inflammatory activity and signs
of thyroid gland injury (Table 2). Both patients with pSS and sSS
had elevated levels of IgA and IgM. IgA was higher in patients with
sSS, while IgG was markedly higher in patients with pSS. ANA pos-
itivity was more common in pSS. Patients with pSS had lower GFR
and higher proteinuria. Dyspnea and pulmonary fibrosis were
slightly more prevalent in sSS (Table 2). Patients with pSS had a
higher frequency of hypertension, left ventricle hypertrophy and
arrythmia/conduction blocks while sSS patients more often suf-
fered from myocarditis and heart failure. Signs of gastrointestinal
tract involvement were evenly distributed between groups.
Patients in whom disease onset began with fever or signs of
other systemic diseases had on average 6–7 years shorter duration
of SS diagnosis establishment (Table 3). Those with OOD or arthri-
tis had a prolonged time till SS diagnosis. In patients with pSS there
was a significant difference in the duration till diagnosis between
those with and without OOD (p < 0.05) (Fig. 1). There was signifi-
cant difference for fever and a tendency for arthritis as the first
manifestations of SS. Both of these trends disappeared after exclu-
sion of patients with sSS from the analysis. For patients with pSS a
significant difference of diagnosis survival curves remained.
Analysis of Cox proportional-hazards regression models for the
diagnosis of SS showed no significance (Table 4). After excluding
patients with sSS, addition of hematological findings in the major-
ity of combinations had a notable effect on the duration till SS
diagnosis.e.
= 24)
pSS (n = 19) sSS (n = 5) p
7 (36.8) 2 (40) 1
14 (73.7) 5 (1 0 0) 0.54
4 (21.1) 1 (20) 1
1 (5.3) 3 (60) 0.02
1 (5.3) 2 (40) 0.09
10 (82.3) 2 (50) 0.24
7 (50) 5 (1 0 0) 0.12
7 (36.8) 0 (0) –
5 (26.3) 5 (1 0 0) 0.01
5 (38.5) 0 (0) –
6 (35.3) 0 (0) 0.52
2 (20) 1 (25) 1
22 (20.5–25.5) 26 (25–27.5) 0.26
10 (52.6) 4 (80) 0.35
1 (7.7) 1 (25) 0.42
10 (52.6) 4 (80) 0.69
11 (57.9) 4 (80) 0.57
nary artery pressure. IQR: interquartile range. Bold values are significant at p < 0.05
pSS patients (n = 19)
p Present Absent p
0.16 3 (4.2–6.7) 9 (3–17) 0.54
0.14 14 (8.5–17) 8 (3–10.5) 0.42
0.08 11 (10–19) 4.5 (3–8) 0.049
0.22 4.5 (3.2–7.2) 10 (3–17) 0.33
nificant at p < 0.05.
ill diagnosis and clinical profile of Sjögren’s syndrome: Data from real clin-
i.org/10.1016/j.ejr.2019.05.003
Table 4
Cox-regression analysis of laboratory investigations for Sjögren’s syndrome diagnosis in all patients (n = 24).
Positive laboratory investigations Sjögren’s syndrome patients
All (n = 24) pSS (n = 19)
RR CI p RR CI p
OOD only 0.61 (0.26–1.44) 0.26 0.27 (0.09–0.81) 0.02
Ocular/Oral Dryness plus CRP 0.7 (0.16–3.06) 0.63 0.54 (0.12–2.52) 0.43
RF 0.46 (0.18–1.22) 0.12 0.18 (0.05–0.67) 0.01
ESR 0.53 (0.18–1.57) 0.25 0.39 (0.13–1.21) 0.1
ANA 0.35 (0.05–2.69) 0.31 0.25 (0.03–2.03) 0.2
CRP/RF 0.56 (0.22–1.42) 0.22 0.26 (0.08–0.88) 0.03
CRP/ESR 0.5 (0.19–1.32) 0.16 0.22 (0.06–0.81) 0.02
CRP/ANA 0.7 (0.16–3.06) 0.63 0.54 (0.12–2.52) 0.43
RF/ESR 0.53 (0.18–1.57) 0.25 0.39 (0.13–1.21) 0.1
RF/ANA 0.46 (0.18–1.22) 0.12 0.18 (0.05–0.67) 0.01
ESR/ANA 0.53 (0.18–1.57) 0.25 0.39 (0.13–1.21) 0.1
CRP/RF/ESR 0.58 (0.24–1.41) 0.23 0.26 (0.08–0.82) 0.02
CRP/RF/ANA 0.56 (0.22–1.42) 0.22 0.26 (0.08–0.88) 0.03
RF/ESR/ANA 0.5 (0.19–1.32) 0.16 0.22 (0.06–0.81) 0.02
CRP/ESR/ANA 0.5 (0.19–1.32) 0.16 0.22 (0.06–0.81) 0.02
CRP/RF/ESR/ANA 0.58 (0.24–1.41) 0.23 0.26 (0.08–0.82) 0.02
pSS: primary SS; OOD, ocular/oral dryness; CRP, C-reactive protein; RF, rheumatoid factor; ESR, erythrocyte sedimentation rate; ANA, antinuclear antibodies. RR: risk ratio; CI:
confidence interval. Bold values are significant at p < 0.05.
Fig. 1. Survival curves of Sjögren’s syndrome duration till diagnosis depending on the first symptom.
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Sjogren’s syndrome (SS) is one of the most common chronic
autoimmune rheumatic disease and considered a high burden dis-
ease [18]. SS is a connective tissue disease (CTD) that mainly affects
the lacrimal and salivary glands [19]. In addition to the sicca
symptoms, morbidity arises also from extra-glandular manifesta-
tions. Proper diagnosis in due time should improve the current
standards of care [18]. pSS is a slowly progressive disease charac-
terized by lymphocytic infiltration of the exocrine glands leading
to sicca manifestations. It may affect any organ thus initially pre-
senting by extraglandular manifestations causing a delay in the
diagnosis. In the past years, better knowledge of the disease has
led to improvement in treatment management [20].
In the present work, SS was more prominent in females. SS pri-
marily affects women [21]. The age and gender in this work werePlease cite this article as: O. Kuryata, T. Lysunets, I. Karavanska et al., Duration t
ical practice in a single-center cohort, The Egyptian Rheumatologist, https://docomparable to those of previous European studies [3,4,6]. All the
current patients with symptoms of OOD were prescribed choli-
nolytic drugs, artificial saliva and eye drops. Most of the patients
received low-dosage steroids and a considerable number received
immunosuppressives. Topical treatment of mucosal dryness is a
mainstay therapeutic strategy and SS patients may also require
treatment with immunomodulatory agents and immunosuppres-
sives for a variety of extraglandular manifestations [21].
Even though it is 1 of the 3 most frequent CTDs alongside sys-
temic lupus erythematosus (SLE) and progressive systemic sclero-
sis (PSS), SS is the least researched. SS poses a potential diagnostic
challenge as it shares many clinical and immunologic features with
other CTDs [19]. In this study, only 5 cases had sSS compared to 19
with pSS. sSS was found to be associated with immune dysfunction
[22], disease activity and comorbidities [23] in RA patients as well
as with SLE [24] and cutaneous vasculitis [25]. When SS isill diagnosis and clinical profile of Sjögren’s syndrome: Data from real clin-
i.org/10.1016/j.ejr.2019.05.003
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found less frequently than in pSS. When SS is associated with
SLE or SSc, clinical and serological patterns are similar to those of
pSS [26].
The frequency of symptoms of OOD and RF positivity were com-
parable to those of other European studies [3,4,6], however there
were substantial differences in clinical presentations from those
in Asian, Hispanic and African-American patients [3,4,27]. When
compared to patients from French cohort [3], our patients more
often presented with Raynaud’s phenomenon and cryoglobuline-
mia. Frequencies of articular and pulmonary involvement in both
cohorts were similar. The present patients more frequently had
objective oral dryness and enlarged salivary glands after ultra-
sound imaging which, along with cryoglobulinemia may be
regarded as a predictor of lymphoma development [28].
The median duration till diagnosis of SS in this study was
8.5 years, which is longer than that in the SICCA registry report
[6]. According to the SS foundation’s initiative, launched in 2012,
SS diagnosis duration should have decreased by 50% in five years.
In 2017, the foundation reported decrease of SS diagnosis to three
years and less [29]. They declared 3 helpful principles in achieving
this goal including increasing public awareness, enhancing educa-
tion and awareness among healthcare professionals and involving
friends and partners [29].
Comparing this registry to existing reports, more similarities
were found with European subgroups of the French [3] and Sjögren
Big Data Project [4] cohorts rather than with the SICCA [6] study. In
all of three mentioned studies there were higher rates of elevated
ANA titer compared to that in this work. Patients from SICCA cohort
had fewer extraglandular manifestations (Raynaud’s phenomenon,
rash and joint involvement), than in our and French cohorts.
Although to the SICCA registry were included two European centers
(in UK and Denmark), presence of patients from Asia and America
may complicate comparison of this register to ours [3,6]. Patients
from our study had characteristics similar to European subgroups
of Sjögren Big Data Project cohort, however, they cannot be clearly
relegated to either Northern or Southern European populations
[4]. Thyroid gland involvement is supposed to be related to SS [6].
Patients in our study experienced a number of thyroid gland abnor-
malities, which, along with high rates of another extraglandular
abnormality may be explained by presence of atypical antibodies
[30]. On the other hand, rate of thyroid gland involvement may be
influenced by another factor – Chernobyl accident [31].
There was heterogeneity of clinical presentations in primary
and secondary SS cases. In both groups glandular and extraglandu-
lar manifestations were similar except for skin hyperpigmentation,
atrophy and myocarditis, but underlying immunological abnor-
malities were quite different. The presence of 3 patients secondary
to SSc affected the difference in skin changes. pSS patients were
characterized by lower GFR and higher frequency of anemia and
proteinuria. This finding cannot be explained by age differences
or discrepancy in BP values.
There was a remarkable paradoxal impact of OOD symptoms on
the duration till diagnosis of SS. In our opinion it may happen
because primary care physicians are not prone to consider these
complaints as a sign of autoimmune disease. According to local
standards, SS is an orphan disease in Ukraine [32]. The augmenta-
tion of this phenomenon after exclusion of patients with sSS from
the analysis confirms a key message that pSS and sSS patients
should be analyzed separately. Thus, in an attempt to find labora-
tory signs that are routinely available at primary outpatient care
level that could be helpful in suspecting SS, CRP, RF and ESR have
been selected as markers of systemic inflammatory reaction and
ANA titer as a marker of autoimmune inflammation.
Impact of different autoantibody fractions in SS diagnosis is
revised constantly: both anti-SSA and anti-SSB antibodies werePlease cite this article as: O. Kuryata, T. Lysunets, I. Karavanska et al., Duration t
ical practice in a single-center cohort, The Egyptian Rheumatologist, https://dopresent in diagnostic criteria until 2012 [9–11]. In 2016 only
anti-SSA antibodies were selected as the most specific for SS
[12]. This decision was partly influenced by Baer et al. who showed
that anti-SSB only (without anti-SSA) positivity is poorly associ-
ated with typical SS clinical manifestations [33]. Nimwegen et al.
[13] and Kontny et al. [30] confirmed that anti-SSA positivity has
stronger relation to symptoms of SS and immunological
abnormalities.
ANA and RF, present in 1993 [9] and 2012 [11] versions of diag-
nostic criteria were excluded in 2016 [12]. After Cox-regression
analysis we discovered that, generally, RF positive patients at the
moment of SS diagnosis, had had longer course of SS before admis-
sion to the rheumatology department and was more fair for
patients with pSS. It may be partly explained by low specificity
of RF for SS diagnosis [3,6,8] together with high frequency of pol-
yarthritis in the current study. In previous report RF was also asso-
ciated with both glandular and articular involvement in patients
with pSS [34]. It could force physicians to look for inflammatory
joint diseases in RF positive patients and ignore complaints of
OOD. The shortest duration till SS diagnosis was in CRP, ANA or
CRP/ANA positive patients. Probably, high ANA titer and elevated
CRP are associated with more aggressive course of SS or these val-
ues were more specific for pSS in this study. Elevated ANA titer was
more frequent than positive RF [3,4,6] thus indicating its superior-
ity in diagnosis of SS.
Among the limitations of this work, patients with symptoms of
OOD were consulted by ophthalmologists or oral and maxillofacial
surgeons, respectively. All diagnostic manipulations as the Schir-
mer’s test, ocular staining, salivary gland visualization and biopsy
were performed outside the rheumatology department. We had
to rely on other physicians’ conclusions regarding the diagnosis
of objective xerostomy, keratoconjunctivitis and the nature of sali-
vary gland involvement. However we had no access to the results
of above-mentioned tests. Improvement in the diagnosis of SS
may be achieved via implementing the following diagnostic tests
for suspected patients in primary care: unstimulated whole saliva
flow measurement, Schirmer’s test, evaluation of CRP level and
ANA titer. Of note, dental caries may be useful in suspecting SS
[27].
In conclusion, a substantial time gap between the first symp-
toms and diagnosis of SS establishment was observed. Patients
with symptoms of OOD at the disease onset had significantly pro-
longed duration till diagnosis. Positive CRP or a high ANA titer may
indicate pSS in patients with OOD symptoms.Acknowledgment
The authors thank Arina Biriukova (C1 English level), an editor,
Skyeng English school, Dnipro, Ukraine, for language editing.Declaration of Competing Interest
None.Funding
This research did not receive any specific grant from funding
agencies in the public, commercial, or not-for-profit sectors.References
[1] Fox RI. Sjögren’s syndrome. Lancet 2005;366:321–31.
[2] Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al. Epidemiology of primary
Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis
2015;74:e25.ill diagnosis and clinical profile of Sjögren’s syndrome: Data from real clin-
i.org/10.1016/j.ejr.2019.05.003
6 O. Kuryata et al. / The Egyptian Rheumatologist xxx (xxxx) xxx[3] Maldini C, Seror R, Fain O, Dhote R, Amoura Z, De Bandt M, et al. Epidemiology
of primary Sjögren’s syndrome in a French multiracial/multiethnic area.
Arthritis Care Res (Hoboken) 2014;66:454–63.
[4] Brito-Zerón P, Acar-Denizli N, Zeher M, Rasmussen A, Seror R, Theander E, et al.
Influence of geolocation and ethnicity on the phenotypic expression of primary
Sjögren’s syndrome at diagnosis in 8310 patients: a cross-sectional study from
the Big Data Sjögren Project Consortium. Ann Rheum Dis 2016;76:1042–50.
[5] Cornec D, Chiche L. Is primary Sjögren’s syndrome an orphan disease? A critical
appraisal of prevalence studies in Europe. Ann Rheum Dis 2015;74(3):e25.
[6] Malladi A, Sack K, Shiboski S, Shiboski C, Baer A, Banushree R, et al. Primary
Sjögren’s Syndrome as a systemic disease: a study of participants enrolled in
an international Sjögren’s Syndrome registry. Arthritis Care Res
2012;64:911–8.
[7] Both T, Dalm VASH, Van Hagen PM, Van Daele PLA. Reviewing primary
Sjögren’s syndrome: beyond the dryness – from pathophysiology to diagnosis
and treatment. Int J Med Sci 2017;14:191–200.
[8] Beckman KA, Luchs J, Milner MS. Making the diagnosis of Sjögren’s syndrome
in patients with dry eye. Clin Ophthalmol 2016;10:43–53.
[9] Vitali C, Bombardieri S, Moutsopoulos H, Balestrieri G, Bencivelli W, Bernstein
RM, et al. Preliminary criteria for the classification of Sjögren’s syndrome:
results of a prospective concerted action supported by the European
community. Arthritis Rheum 1993;36:340–7.
[10] Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, et al. Classification
criteria for Sjögren’s syndrome: a revised version of the European criteria
proposed by the American-European Consensus Group. Ann Rheum Dis
2002;61(6):554–8.
[11] Shiboski SC, Shiboski CH, Criswell LA, Baer AN, Challacombe S, Lanfranchi H,
et al. American College of rheumatology classification criteria for Sjögren’s
syndrome: a data-driven, expert consensus approach in the Sjögren’s
International Collaborative Clinical Alliance cohort. Arthritis Care Res
2012;64:475–87.
[12] Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al.
2016 american college of rheumatology/european league against rheumatism
classification criteria for primary Sjögren’s syndrome: a consensus and data-
driven methodology involving three international patient cohorts. Arthritis
Rheumatol 2017;69:35–45.
[13] van Nimwegen JF, van Ginkel MS, Arends S, Haacke EA, van der Vegt B, Smitt-
Kamminga NS, et al. Original article validation of the ACR-EULAR criteria for
primary Sjogren’s syndrome in a Dutch prospective diagnostic cohort.
Rheumatology 2018;67:818–25.
[14] Gomes PDS, Juodzbalys G, Fernandes MH, Guobis Z. Diagnostic approaches to
Sjögren’s syndrome: a literature review and own clinical experience. J Oral
Maxillofac Res 2012;3:e3.
[15] Shiboski C, Baer A, Shiboski C, Lam M, Challacombe S, Lanfranchi HE, et al.
Natural history and predictors of progression to Sjögren’s syndrome among
participants of the SICCA registry. Arthritis Care Res (Hoboken)
2018;70:284–94.
[16] Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy
as obtained by unipolar precordial and limbs leads. Am Heart J
1949;37:161–86.
[17] Eknoyan G, Lameire N, Echardt K, Kasiske B, Wheeler D, Abboud O. KDIGO
2012 clinical practice guideline for the evaluation and management of chronic
kidney disease. Kidney IntSuppl 2013;3:1–150.Please cite this article as: O. Kuryata, T. Lysunets, I. Karavanska et al., Duration t
ical practice in a single-center cohort, The Egyptian Rheumatologist, https://do[18] Vivino FB. Sjogren’s syndrome: Clinical aspects. Clin Immunol
2017;182:48–54.
[19] Jhorar P, Torre K, Lu J. Cutaneous features and diagnosis of primary Sjögren
syndrome: An update and review. J Am Acad Dermatol 2018;79(4):736–45.
[20] Gómez Rosas, de Salazar J, Senabre Gallego JM, Santos Ramírez C. Management
of the extraglandular manifestations of primary Sjögrens syndrome. Reumatol
Clin 2010;6(Suppl 2):6–11.
[21] Baer AN, Walitt B. Update on Sjögren syndrome and other causes of sicca in
older adults. Rheum Dis Clin North Am. 2018;44(3):419–36.
[22] Sherif Nahed Mounir, Arafa Mona Mahmoud, Ibrahim Soha Eldessouki, Moussa
Salwa Galal. CXC ligand 13 in rheumatoid arthritis and its relation to
secondary Sjögren’s syndrome. Egypt Rheumatol 2013;35(3):121–6. doi:
https://doi.org/10.1016/j.ejr.2013.03.004.
[23] Gheita TA, Kenawy SA, El Sisi RW, Gheita HA, Khalil H. Subclinical reduced
G6PD activity in rheumatoid arthritis and Sjögren’s Syndrome patients:
relation to clinical characteristics, disease activity and metabolic syndrome.
Mod Rheumatol 2014;24(4):612–7.
[24] Pasoto SG, de Oliveira Adriano, Martins V, Bonfa E. Sjögren’s syndrome and
systemic lupus erythematosus: links and risks. Open Access Rheumatol
2019;11:33–45.
[25] Gheita TA, Abaza NM, Sayed S, El-Azkalany GS, Fishawy HS, Eissa AH.
Cutaneous vasculitis in systemic lupus erythematosus patients: potential
key players and implications. Lupus 2018;27(5):738–43. doi: https://doi.org/
10.1177/0961203317739134.
[26] Salliot C, Mouthon L, Ardizzone M, Sibilia J, Guillevin L, Gottenberg JE, et al.
Sjogren’s syndrome is associated with and not secondary to systemic sclerosis.
Rheumatology (Oxford) 2007;46(2):321–6.
[27] Zhao Y, Li Y, Wang L, Xiao-Feng L, Huang C-B, Wang G-C, et al. Primary sjogren
syndrome in han chinese. Medicine (Baltimore) 2015;94:1–8.
[28] Alunno A, Leone MC, Giacomelli R, Gerli R, Carubbi F. Lymphoma and
lymphomagenesis in primary Sjögren’s syndrome. Front Med (Lausanne)
2018;5:1–7.
[29] Sjogren’s Syndrome Foundation. SSF 5-Year breakthrough goal update: the
average Sjögren’s diagnosis time decreases to 3 Years! Moisture Seek
2017;35:1.
[30] Kontny E, Lewandowska-Poluch A, Chmielin´ska M, Olesin´ska M. Subgroups of
Sjögren’s syndrome patients categorised by serological profiles: clinical and
immunological characteristics. Reumatologia 2018;56(6):346–53.
[31] Antonenko AM, Korshun MM, Vavrinevych OP, Omelchuk ST, Bardov VH.
Epidemiologic evaluation of thyroid diseases morbidity of ukrainian adult
population from 2000 To 2013. Int J Med Med Res 2018;4:52–9.
[32] Health Ministry of Ukraine. Approval of the list of rare (orphan) diseases.
Ukraine 2014.
[33] Baer AN, McAdams DeMarco M, Shiboski SC, Lam MY, Challacombe S, Daniels
TE, et al. The SSB-positive/SSA-negative antibody profile is not associated with
key phenotypic features of Sjögren’s syndrome. Ann Rheum Dis
2015;74:1557–61.
[34] Brito-Zeron P, Acar-Denizli N, Ng WF, Zeher M, Rasmussen A, Mandl T, et al.
How immunological profile drives clinical phenotype of primary Sjögren’s
syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project).
Clin Exp Rheumatol 2018;36:102–12.ill diagnosis and clinical profile of Sjögren’s syndrome: Data from real clin-
i.org/10.1016/j.ejr.2019.05.003
